1. Home
  2. XFOR vs LPTX Comparison

XFOR vs LPTX Comparison

Compare XFOR & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XFOR
  • LPTX
  • Stock Information
  • Founded
  • XFOR 2014
  • LPTX 2011
  • Country
  • XFOR United States
  • LPTX United States
  • Employees
  • XFOR N/A
  • LPTX N/A
  • Industry
  • XFOR Biotechnology: Biological Products (No Diagnostic Substances)
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • XFOR Health Care
  • LPTX Health Care
  • Exchange
  • XFOR Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • XFOR 118.4M
  • LPTX 117.1M
  • IPO Year
  • XFOR N/A
  • LPTX N/A
  • Fundamental
  • Price
  • XFOR $0.40
  • LPTX $2.74
  • Analyst Decision
  • XFOR Strong Buy
  • LPTX Strong Buy
  • Analyst Count
  • XFOR 4
  • LPTX 4
  • Target Price
  • XFOR $2.88
  • LPTX $8.63
  • AVG Volume (30 Days)
  • XFOR 4.9M
  • LPTX 452.0K
  • Earning Date
  • XFOR 11-13-2024
  • LPTX 11-13-2024
  • Dividend Yield
  • XFOR N/A
  • LPTX N/A
  • EPS Growth
  • XFOR N/A
  • LPTX N/A
  • EPS
  • XFOR N/A
  • LPTX N/A
  • Revenue
  • XFOR $1,123,000.00
  • LPTX N/A
  • Revenue This Year
  • XFOR N/A
  • LPTX N/A
  • Revenue Next Year
  • XFOR $596.79
  • LPTX N/A
  • P/E Ratio
  • XFOR N/A
  • LPTX N/A
  • Revenue Growth
  • XFOR N/A
  • LPTX N/A
  • 52 Week Low
  • XFOR $0.26
  • LPTX $1.55
  • 52 Week High
  • XFOR $1.60
  • LPTX $5.00
  • Technical
  • Relative Strength Index (RSI)
  • XFOR 39.99
  • LPTX 39.77
  • Support Level
  • XFOR $0.26
  • LPTX $3.40
  • Resistance Level
  • XFOR $0.68
  • LPTX $3.61
  • Average True Range (ATR)
  • XFOR 0.08
  • LPTX 0.40
  • MACD
  • XFOR -0.01
  • LPTX -0.13
  • Stochastic Oscillator
  • XFOR 34.01
  • LPTX 1.91

About XFOR X4 Pharmaceuticals Inc.

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: